Enfusion, Inc. (NYSE:ENFN) Short Interest Up 41.9% in January

Enfusion, Inc. (NYSE:ENFN) was the target of a large increase in short interest in January. As of January 31st, there was short interest totalling 1,010,000 shares, an increase of 41.9% from the January 15th total of 711,700 shares. Approximately 2.4% of the company’s stock are sold short. Based on an average daily volume of 797,400 shares, the days-to-cover ratio is presently 1.3 days.

Enfusion Trading Down 1.3 %

Shares of Enfusion stock opened at $11.01 on Friday. The firm’s 50 day simple moving average is $10.76 and its two-hundred day simple moving average is $9.57. The firm has a market capitalization of $1.41 billion, a price-to-earnings ratio of 275.19, a PEG ratio of 1.83 and a beta of 0.96. Enfusion has a 12-month low of $7.83 and a 12-month high of $11.38.

Analysts Set New Price Targets

ENFN has been the topic of a number of analyst reports. Piper Sandler lifted their price objective on shares of Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research report on Monday, December 23rd. Stifel Nicolaus upped their price target on Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Finally, William Blair reissued a “market perform” rating on shares of Enfusion in a research report on Monday, January 13th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, Enfusion presently has a consensus rating of “Hold” and an average target price of $10.50.

Insider Activity

In related news, COO Neal Pawar sold 21,801 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.03, for a total transaction of $218,664.03. Following the sale, the chief operating officer now owns 1,143,544 shares of the company’s stock, valued at $11,469,746.32. This trade represents a 1.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Oleg Movchan sold 2,771 shares of the business’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total transaction of $28,070.23. Following the completion of the transaction, the chief executive officer now owns 526,702 shares of the company’s stock, valued at $5,335,491.26. This represents a 0.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 57,367 shares of company stock worth $591,335. 36.44% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Enfusion

Several hedge funds have recently made changes to their positions in ENFN. KLP Kapitalforvaltning AS purchased a new stake in Enfusion during the 4th quarter valued at about $75,000. Harbor Capital Advisors Inc. raised its position in Enfusion by 12.4% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock worth $113,000 after buying an additional 1,315 shares during the last quarter. Belvedere Trading LLC acquired a new stake in Enfusion during the 3rd quarter valued at approximately $114,000. Dark Forest Capital Management LP purchased a new stake in shares of Enfusion in the 4th quarter valued at $128,000. Finally, Tower Research Capital LLC TRC increased its stake in shares of Enfusion by 58.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 13,227 shares of the company’s stock worth $136,000 after acquiring an additional 4,889 shares during the period. 81.05% of the stock is owned by institutional investors and hedge funds.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.